Pricing Log in Create free account
Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

CYTK Healthcare Biotechnology

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue
+2,356.5%
EPS
+46.3%
Free cash flow
−6.73%
Total debt
−83.9%

Quarter to September 2026, against a year earlier

54.83 0.72 −1.30%
Market cap
$7.7B
P/E
0.0×
Fwd P/E
−10.3×
Dividend yield
—
F-score
2/9
Altman Z
−1.98
Beneish M
−0.44
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cytokinetics, Incorporated (CYTK) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Cytokinetics, Incorporated (CYTK) trades at a EV/Sales of 65.9×. Over the past ten years it has ranged from 2.4× (November 2017) to 2,039× (April 2024); the current reading is higher than 69% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 89.8× (65.78%)
FY2024 262× (75.67%)
FY2023 1,079× 2,576.66%
FY2022 40.3× (11.05%)
FY2021 45.3× 149.12%
FY2020 18.2× (5.97%)
FY2019 19.3× 224.72%
FY2018 6.0× (61.16%)
FY2017 15.3× 342.30%
FY2016 3.5× (67.86%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 78.3× (52.84%)
Jun 2026 166× 107.42%
Mar 2026 80.0× (10.88%)
Dec 2025 89.8× 16.58%
43 more quarters

Against its own ten years

Low 2.4× High 2,039×
Ten-year median 23.7×
Current reading's percentile 67

EV/Sales against peers

Company EV/Sales
CAI Caris Life Sciences,�Inc. compare 6.8×
CORT Corcept Therapeutics Incorporated compare 7.6×
MDGL Madrigal Pharmaceuticals, Inc. compare 7.8×
ARWR Arrowhead Pharmaceuticals, Inc. compare 11.2×
KRYS Krystal Biotech, Inc. compare 17.0×
TWST Twist Bioscience Corporation compare 17.3×
PTGX Protagonist Therapeutics, Inc. compare 28.9×
CYTK Cytokinetics, Incorporated 65.9×
SYRE Spyre Therapeutics, Inc. compare 7,143×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CYTK